Sun Pharma Advanced Research Company (SPARC) has applied to the US Food and Drug Administration (FDA) for approval to start human trials of a new cancer treatment called SBO-154. The company has submitted an Investigational New Drug (IND) application, which is required before beginning clinical trials.
SBO-154 has already gone through preclinical studies (tests done in labs and on animals) and has shown promising results. Now, SPARC plans to conduct a global Phase 1 trial to test the safety and effectiveness of the drug in treating solid tumors.
Read More: Are You Thinking of Getting a Tattoo? A New Study Links Ink to Cancer Risk! Read Before You Ink!
Anil Raghavan, CEO of SPARC, said, “SBO-154 is our first Antibody-Drug Conjugate (ADC), and moving to Phase 1 trials is a major achievement for us. We aim to bring better treatment options for cancer patients worldwide.”
SBO-154 is a specially designed drug that targets a protein called MUC1-SEA, which is found in advanced solid tumors. It works by attaching to the tumor cells and releasing a powerful anti-cancer substance inside them. This stops the cells from dividing and helps shrink the tumor.
Also See: AI Might Save Your Life! It Can Detect Heart Issues Before They Turn Deadly, Read Now
SPARC developed SBO-154 after licensing an anti-MUC1 antibody from Biomodifying, a startup from the University of Tel Aviv.
